Cencora (COR) Expected to Announce Quarterly Earnings on Wednesday

Cencora (NYSE:COR - Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, February 5th. Analysts expect Cencora to post earnings of $3.50 per share and revenue of $78.22 billion for the quarter. Parties interested in participating in the company's conference call can do so using this link.

Cencora Stock Down 1.7 %

COR stock traded down $4.35 during midday trading on Friday, hitting $254.11. The company's stock had a trading volume of 1,916,988 shares, compared to its average volume of 1,137,066. Cencora has a 52-week low of $214.77 and a 52-week high of $261.25. The firm has a 50-day simple moving average of $238.74 and a 200-day simple moving average of $235.90. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The firm has a market capitalization of $49.11 billion, a P/E ratio of 33.84, a PEG ratio of 1.61 and a beta of 0.49.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.87%. This is a boost from Cencora's previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. Cencora's payout ratio is presently 29.29%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on COR. Mizuho assumed coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 target price on the stock. UBS Group lifted their price objective on shares of Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Evercore ISI increased their target price on Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Leerink Partners decreased their price target on Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a report on Monday, October 7th. Finally, Wells Fargo & Company increased their price objective on Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Cencora has a consensus rating of "Moderate Buy" and a consensus price target of $278.40.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now directly owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the business's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 73,187 shares of company stock worth $17,790,912 in the last quarter. 10.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.